Melissa Bloch, MD
Payments from drug & device makers
Across 1,189 payments — averaging $920.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$256K
- EMD Serono, Inc.$243K
- Biogen$242K
- Genentech USA, Inc.$136K
- AstraZeneca$75K
- E.r. Squibb & Sons, L.L.C.$66K
- plus $77K from 15 others
Across 13 payments — averaging $143.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 145 | $255,532 |
| EMD Serono, Inc. | 279 | $242,774 |
| Biogen | 280 | $241,786 |
| Genentech USA, Inc. | 132 | $136,261 |
| AstraZeneca(2 entities) | 121 | $75,232 |
| E.r. Squibb & Sons, L.L.C. | 56 | $65,540 |
| TG Therapeutics, Inc. | 29 | $39,804 |
| Novartis | 50 | $16,961 |
| Bristol Myers Squibb | 39 | $13,565 |
| Banner Life Sciences, LLC | 12 | $4,001 |
| Genentech, Inc. | 3 | $1,144 |
| Amgen(2 entities) | 26 | $967 |
| AbbVie(2 entities) | 7 | $137 |
| Kyowa Kirin, Inc. | 1 | $115 |
| Pfizer | 3 | $91 |
| Neuropace, Inc. | 1 | $43 |
| Argenx US, Inc. | 1 | $29 |
| Johnson & Johnson | 1 | $28 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $21 |
| SK Life Science, Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
How this compares
$1,094,056 in reported general payments places this provider in the 95th percentile of 145 neurology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Reno
- Lee GerwitzReno$415K
- Burton TabaacReno$287K
- G BigleyReno$134K
- Verena SamaraReno$64K
- Christopher WayReno$57K
- Frank QuaglieriReno$21K
- Timothy LouieReno$15K
- Yen-Yi PengReno$14K
- Danny TruongReno$12K
- Rolando AniaReno$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.